Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Genome Biology|October 29, 2014
MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysisPeilin Jia, Quan Wang, Qingxia Chen, et al.
Oncotarget|December 25, 2014
Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approachWei Jiang, Peilin Jia, Katherine E Hutchinson, et al.
Molecular Cancer Therapeutics|April 24, 2014
A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevanceJunfeng Xia, Peilin Jia, Katherine E Hutchinson, et al.
JCO Precision Oncology|November 29, 2022
Comparison of <i>PIK3CA</i> Mutation Prevalence in Breast Cancer Across Predicted Ancestry PopulationsJessica W Chen, Karthikeyan Murugesan, Justin Y Newberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA MutationsSmruthy Sivakumar, Dexter X Jin, Ruchita Rathod, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2019
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype ShiftsKatherine E Hutchinson, Susan E Yost, Ching-Wei Chang, et al.
BMC Cancer|January 23, 2019
CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancerZi-Ming Zhao, Susan E Yost, Katherine E Hutchinson, et al.
Nature Cancer|April 10, 2023
Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumabArash Nabbi, Arnavaz Danesh, Osvaldo Espin-Garcia, et al.
Oncotarget|June 19, 2015
ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanomaKatherine E Hutchinson, Douglas B Johnson, Adam S Johnson, et al.
The Lancet. Oncology|November 30, 2019
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 studyBirgit Geoerger, C Michel Zwaan, Lynley V Marshall, et al.
Pageof 4